Evaluation of Kagocel Genotoxicity


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Somente assinantes

Resumo

Antiviral drug Kagocel in concentrations of 0.0008, 0.004, 0.02, 0.1, 0.5, and 2.5 mg/ml with or without metabolic activation does not induce gene mutations in S. typhimurium strains ТА98, ТА100, ТА1535, and ТА1537 and in a combination of E. coli strains pKM101 and uvrA. A single intragastric administration of Kagocel in a daily therapeutic dose and a 10-fold daily therapeutic dose to male mice or multiple administrations in daily therapeutic dose to male and female mice did not led to a significant increase in the percentage of chromosomal aberrations in the bone marrow cells. DNA comet assay revealed no significant increase in the incidence of DNA breaks in cells of mouse testes after single or multiple administration of Kagocel at daily therapeutic and 10-fold daily therapeutic doses. Our results indicate that Kagocel exhibits no genotoxic activity in the studied dose range.

Sobre autores

S. Kamalova

E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center, Russian Academy of Sciences

Email: zhanataev@academpharm.ru
Rússia, Tomsk

A. Durnev

V. V. Zakusov Research Institute of Pharmacology

Email: zhanataev@academpharm.ru
Rússia, Moscow

A. Zhanataev

V. V. Zakusov Research Institute of Pharmacology

Autor responsável pela correspondência
Email: zhanataev@academpharm.ru
Rússia, Moscow

T. Borovskaya

E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center, Russian Academy of Sciences

Email: zhanataev@academpharm.ru
Rússia, Tomsk

B. Shcherbakova

Niarmedic Pharma Company

Email: zhanataev@academpharm.ru
Rússia, Moscow

B. Rudoi

Niarmedic Pharma Company

Email: zhanataev@academpharm.ru
Rússia, Moscow

A. Vychuzhanina

E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center, Russian Academy of Sciences

Email: zhanataev@academpharm.ru
Rússia, Tomsk

V. Grigor’eva

E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center, Russian Academy of Sciences

Email: zhanataev@academpharm.ru
Rússia, Tomsk


Declaração de direitos autorais © Springer Science+Business Media, LLC, part of Springer Nature, 2019

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies